AAAAI

AAAAI 2024. The effects, seen 18 to 20 weeks after discontinuation of tezepelumab, suggest a persistent effect of thymic stromal lymphopoietin (TSLP) blockade in CSU.

AAAAI 2023. The TSLP inhibitor was superior to placebo in 2 post hoc analyses of the PATHWAY and NAVIGATOR clinical trials.

Future studies may consider PARS the new gold standard in predicting pediatric asthma risk, said study authors.

AAAAI 2023. Pandemic prescribing rates for systemic corticosteroids increased from Alpha to Delta to Omicron waves of COVID-19 but hospitalizations have dropped, study finds.

Recent research presented at AAAAI 2021 Virtual Annual Meeting suggests asthma is not an independent risk factor for severe COVID-19 or hospitalization.

Statistically significant reductions in annual exacerbation rates were seen across baseline eosinophil and exhaled FeNO level and allergy status with telepezumab, in the phase 3 NAVIGATOR trial.

Treatment for severe asthma may be enhanced using an online decision support tool that draws on expert treatment decisions for a wide variety of potential patient scenarios.

Patients with COVID-19 who have asthma share a similar risk of hospitalization with patients with the infection who do not have asthma, according to new research.

AAAAI Virtual Annual Meeting. Among patients with asthma, wearing a mask, regardless of type or duration of use, had no significant effect on oxygen saturation.

Get a first look at key 8 studies to be presented at the upcoming AAAAI 2021 virtual meeting starting this Friday, February 26, 2021.